Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04421560
Title Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Dana Farber Cancer Institute RECRUITING Boston Massachusetts 02115 United States Details
Columbia University Medical Center WITHDRAWN New York New York 10032 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field